Frequently Asked Questions

The prize entry period is now closed

This FAQ is intended to answer any questions you may have on the Longitude Prize on AMR, providing key information on the prize, and further information for participants who have entered.

For full details please read the Prize Rules and Terms and Conditions.

Prize Background

The Longitude Prize on AMR is an £8 million prize that will reward a team of innovators who develop a point–of–care diagnostic test that will conserve antibiotics for future generations. The test must be accurate, rapid, affordable and easy to use anywhere in the world.

The Prize Advisory Panel (i.e. the judging panel) provides expert independent scientific and technical guardianship for the Longitude Prize on AMR. Drawing on their wide-ranging expertise they will make judgements and recommendations to the Longitude Prize Committee regarding the allocation of the prize. The Longitude Prize Committee will make the final decision as to whether a submission meets the criteria to win the prize.

The winning team must spend their prize money to develop and market their product as proposed in their winning submission so that it can create maximum global benefit and achieve the aims of the Longitude Prize. This requirement may be relaxed if the winning team can prove to the Longitude Committee that they will be able to create maximum global benefit and achieve the aims of the Longitude Prize without further development, for example, show that it will be utilised for public benefit through openly licensing their intellectual property or demonstrating sufficient funding to commercialise their product.

Yes, there will only be one winner. A decision on the outcome of the prize can be expected in early 2024.

The decision was based on expert advice that a diagnostic test delivering a result in up to 60-minutes would provide significant utility and impact on clinical decision-making, helping clinicians to prescribe an effective antibiotic in the first instance. Test developers must demonstrate that the time-to-result of their test is in line with current clinical practice in the clinical pathway where the test will be used, and if not, how they intend to overcome this issue.

More information about our Prize Rules can be found here.

The Longitude Prize on Dementia launched in September 2022. It will award £4.42m in seed funding, grants and prizes to technologies that use AI and machine learning to learn about a user with early stage dementia and adapt to their changing condition as the disease progresses. The technologies should be designed to be used by a person living with early stage dementia to help them remain independent and keep doing the things that bring them fulfilment and enjoyment for as long as possible. Entries to the Longitude Prize on Dementia close on 26 January 2023.

Find out more about the Longitude Prize on Dementia, or how to get in touch to deliver your own Longitude Prize here.

Current status of the Prize

The Longitude Prize on AMR closed for applications on 30 September 2022. 

Competitors’ submissions have been reviewed by the Prize Advisory Panel, against the criteria to win the prize outlined in the Prize Rules. Those that met the criteria were interviewed by the Prize Advisory Panel.

After the interviews, teams were invited to undergo independent testing to address outstanding questions from the Prize Advisory Panel. Tests are being validated within their intended use settings to determine whether they produce valid results that are concordant with the reference standard of testing. 

After assessing the results, the Prize Advisory Panel will form final recommendations to the Longitude Committee on whether to award the prize.

A final decision on the outcome of the prize can be expected in early 2024.

The Longitude Committee will make a decision on the outcome of the prize in early 2024.